Genmab — April 2025
-
Fra MW "Genmab har fået løftet kursmålet for sin amerikanske notering til 29 dollar fra 27 dollar hos den amerikanske investeringsbank Leerink Partners.
Det viser data fra Bloomberg News.
Anbefalingen er stadig "outperform".
Der går ti af Genmabs ADR-aktier på én dansk. Det nye kursmål svarer således til 1877,90 kr."
-
Transactions in Connection with Share Buy-back Program https://proinvestor.com/investornyt/1306225/transactions-in-connection-with-share-buy-back-program
-
Amerikansk politik presser biotekaktierne https://proinvestor.com/investornyt/1306176/amerikansk-politik-presser-biotekaktierne
-
https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-april-2025_en.pdf Teprotumumab
on EMA CHMP agenda -
more for the academics i guess, as it has been terminated - DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma https://elifesciences.org/reviewed-preprints/106425#x1684353369
-
ASCO25 Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with epcoritamab (epcor) monotherapy.
Abstract: 7043
| Poster Bd #: 226
-
Roche Ocrevus sales Q1 25 CHF 1778mn, Columvi 60m, Lunsumio 21m ( via https://www.roche.com/investors )
-
BioNTech at AACR 2025 -Preclinical data for the EpCAMx4-1BB antibody candidate BNT314/GEN1059, which is being developed in collaboration with Genmab S/A (“Genmab”), will be presented in a poster session. BNT314/GEN1059 was evaluated in combination with PD-1 inhibition in a tumor model unresponsive to each single treatment. https://www.biospace.com/press-releases/biontech-to-present-clinical-and-preclinical-data-across-mrna-and-next-generation-immuno-oncology-priority-programs-at-aacr-2025
-
The data showed anti-tumor activity, delayed tumor outgrowth and prolonged survival for the combination treatment compared to both single treatments. The immunomodulatory activity of BNT314/GEN1059 was further potentiated in combination with PD-1 blockade.
-
this patient still surviving on epcoritamab https://thepatientstory.com/patient-stories/non-hodgkin-lymphoma/diffuse-large-b-cell-dlbcl/michael-e/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind